cytarabine 100mg/ml injection 100mg/ml (10ml)
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents
cytarabine 100mg/ml injection solution for injection 100mg/ml (20ml)
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents
ara-cell 4 g
mbi pharma ltd., israel - cytarabine - solution for infusion - cytarabine 4000 mg / 80 ml - cytarabine - ara-cell® 4000 mg is indicated for induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas (non-hodgkin's lymphomas of high malignancy).
ara-cell 4 g
mbi pharma ltd., israel - cytarabine - solution for infusion - cytarabine 4000 mg / 80 ml - cytarabine - ara-cell® 4000 mg is indicated for induction and maintenance of clinical remission in patients with acute myeloid leukemia, acute non-lymphoblastic leukemias, acute lymphoblastic leukemias, blast crises of chronic myeloid leukemia, diffuse histiocytic lymphomas (non-hodgkin's lymphomas of high malignancy).
ara-cell 5 g
mbi pharma ltd., israel - cytarabine - concentrate for solution for infusion - cytarabine 5 g / 50 ml - cytarabine - ara-cell® 100 mg/ml is used in combination with other cytostatic agents in high-dose therapy for:• refractory non-hodgkin’s lymphoma• refractory acute non-lymphocytic leukaemia• refractory acute lymphoblastic leukaemia• recurrent cases of acute leukaemia• types of leukaemia with special risk: – secondary leukaemia following previous chemotherapy and/or radiation treatment – manifest leukaemia following transformation of pre-leukaemia• consolidation of the remission of acute non-lymphocytic leukaemia in patients under 60 years of age.
ara-cell 5 g
mbi pharma ltd., israel - cytarabine - concentrate for solution for infusion - cytarabine 5 g / 50 ml - cytarabine - ara-cell® 100 mg/ml is used in combination with other cytostatic agents in high-dose therapy for:• refractory non-hodgkin’s lymphoma• refractory acute non-lymphocytic leukaemia• refractory acute lymphoblastic leukaemia• recurrent cases of acute leukaemia• types of leukaemia with special risk: – secondary leukaemia following previous chemotherapy and/or radiation treatment – manifest leukaemia following transformation of pre-leukaemia• consolidation of the remission of acute non-lymphocytic leukaemia in patients under 60 years of age.
alexan solution for injection/infusion
ebewe pharma ges. m.b.h. nfg. kg - cytarabine - solution for injection/infusion - 20mg/ml
alexan solution for injection/infusion
ebewe pharma ges. m.b.h. nfg. kg - cytarabine - solution for injection/infusion - 50mg/ml
cytosar powder lyophilized for solution for injection
actavis italy s.p.a. - cytarabine - powder lyophilized for solution for injection - 100mg
cytosar powder lyophilized for solution for injection
actavis italy s.p.a. - cytarabine - powder lyophilized for solution for injection - 500mg